Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study

Gynecologic Oncology

Volumn 112, Issue 3, 2009, Pages 563-567

  Hensley, Martee L ^a   Ishill, Nicole ^a   Soslow, Robert ^a   Larkin, Joseph ^a   Abu Rustum, Nadeem ^a   Sabbatini, Paul ^a   Konner, Jason ^a   Tew, William ^a   Spriggs, David ^a   Aghajanian, Carol A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Docetaxel; Gemcitabine; Resected stage I IV; Uterine leiomyosarcoma

Indexed keywords

DEXAMETHASONE; DIURETIC AGENT; DOCETAXEL; GEMCITABINE; PEGYLATED FILGRASTIM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; HYPERSENSITIVITY REACTION; LEIOMYOSARCOMA; LIVER DYSFUNCTION; LUNG CARCINOMA; NEUTROPENIA; OVERALL SURVIVAL; PELVIS; PELVIS CANCER; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; POPULATION RESEARCH; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; STOMATITIS; SURVIVAL TIME; TREATMENT DURATION; UTERUS; UTERUS LEIOMYOSARCOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TAXOIDS; UTERINE NEOPLASMS;

EID: 60449099927     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.11.027     Document Type: Article

References (25)

1. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71 (1993) 1702-1709
2. Nordal R.R., Kristensen G.B., Kaern J., et al. The prognostic significance of stage, tumor size, cellular atypia, and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34 (1995) 797-802
3. Gadducci A., Sartori E., Landoni F., et al. Endometrial stromal sarcoma: analysis of treatment failures and survival. Gynecol. Oncol. 63 (1996) 247-253
4. Dinh T.A., Oliva E.A., Fuller A.F., Lee H., and Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol. Oncol. 92 (2004) 648-652
5. Dinh T.V., and Woodruff J.D. Leiomyosarcoma of the uterus. Am. J. Obstet. gynecol. 144 (1982) 817-823
6. Pautier P., Genestie C., Rey A., et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 (2000) 1425-1431
7. Reed N.S., Mangioni C., Malmstrom H., et al. Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stage I and II: an European Organisation for Research and Treatment of Cancer Gynaecolgic Cancer Group Study (protocol 55874). Eur. J. Cancer 44 (2008) 808-818
8. Omura G.A., Blessing J.A., Major F., et al. A Randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J. Clin. Oncol. 3 (1985) 1240-1245
9. Hensley M.L., Maki R., Venkatraman E., et al. Gemcitabine and Docetaxel in Patients with Unresectable Leiomyosarcoma: results of a Phase II Trial. J. Clin. Oncol. 20 (2002) 2824-2831
10. Hensley M.L., Blessing J., DeGeest K., Abulafia O., Rose P., and Homesley H.D. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol. Oncol. 109 (2008) 323-328
11. Hensley M.L., Blessing J., Mannel R., and Rose P.G. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 109 (2008) 324-329
12. Kushner D.M., Webster K.D., Belinson J., Rybicki L.A., Kennedy A.W., and Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gynecol. Oncol. 78 (2000) 221-227
13. Chauvenic L., Deniaud E., Plancher C., et al. Uterine sarcomas: the Curie Institute experience. Prognosis factors and adjuvant treatments. Gyneocl. Oncol. 72 (1999) 232-237
14. Bramwell V.H.C. Adjuvant chemotherapy for adult soft tissue sarcoma: is there a standard of care. J. Clin. Oncol. 19 (2001) 1235-1237
15. Bell S.W., Kempson R.L., and Hendrickson M.R. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am. J. Surg. Pathol. 18 (1994) 535-558
16. http://ctep.info.nih.gov.
17. Dinh T.A., Oliva E.A., Fuller A.F., Lee H., and Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. Gynecol. Oncol. 92 (2004) 648-652
18. Zivanovic O., Iasonos A., Hensley M.L., et al. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system. Submitted to Gynecologic. Oncology. (August 2008)
19. Pautier P., Genestie C., Rey A., Morice P., Roche B., Lhomme C., et al. Analysis of clinicopathologic prognostic factors for 157 uterin sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer 88 (2000) 1425-1431
20. Omura G.A., Blessing J.A., Major F., et al. A Randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J. Clin. Oncol. 3 (1985) 1240-1245
21. Reed N.S., Mangioni C., Malmstrom H., Scarfone G., Poveda A., Pecorelli S., et al. Phase III randomized study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stage I and II: an European Organisation for Research and Treatment of Cancer Gynaecologic Cancer Group Study (protocol 55874). Eur. J. Cancer 44 (2008) 808-818
22. Zivanovic O., Iasonos A., Leitao M.M., Zhou Q., Soslow R.A., Juretzka M.M., et al. Stage-specific survival of patients with uterine leiomyosarcoma: a comparison of FIGO and AJCC staging system. Proc. Amer. Soc. Clin. Oncol. 26 (2008) abstract 5554
23. Pautier P., Rey A., Maie-Meder C., Kerbrat P., Dutel J.L., Gesta P., et al. Adjuvant chemotherapy with cispatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case-control study with radiotherapy alone. Int. J. Gyn. Cancer 14 (2004) 1112-1117
24. Kushner D.M., Webster K.D., Belinson J.L., Rybicki L.A., Kennedy A.W., and Markman M. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Gyncol. Oncol. 78 (2000) 221-227
25. Odunsi K., monede V., Tammela J., Ghamande S., Seago P., Driscoll, et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: results of long-term follow-up. Int. J. Gynecol. Cancer 14 (2004) 659-664